Business Context and Reporting Period
Company: Armata Pharmaceuticals, Inc. (ARMP)
Filing Type: Form 8-K (Current Report)
Date of Report: October 22, 2025
Reporting Period: Event-based report regarding clinical trial results announced on October 22, 2025.
Key Financial Metrics
This filing is a Current Report on Form 8-K focused on a clinical development milestone. It does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metric.
Material Changes
The material change reported is the announcement of positive results from the recently completed Phase 2a diSArm study of the Company's candidate drug, AP-SA02. The study evaluated the drug as a potential treatment for complicated Staphylococcus aureus bacteremia. These results were presented at IDWeek 2025.
Guidance, Outlook, and Risks
- Management Commentary: The Company issued a press release and an oral presentation by Dr. Loren G. Miller, M.D., M.P.H., detailing the positive study results.
- Forward-Looking Statements: The Company disclaims any duty or obligation to publicly update or revise the information contained in this report, except as required by federal securities laws.
- Risks and Contingencies: The filing notes that the information is summary in nature and should be considered in the context of other SEC filings. It explicitly states that the information is not "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and shall not be incorporated by reference into other registration statements.
Investor Verification Checklist
- Review the full text of the press release (Exhibit 99.1) for specific clinical data points regarding the Phase 2a diSArm study.
- Examine the IDWeek Presentation (Exhibit 99.2) for detailed methodology and statistical significance of the results.
- Verify the Company's cash runway and funding status in the most recent 10-Q or 10-K, as this 8-K contains no financial data.
- Monitor future filings for updates on regulatory strategy or next-phase trial plans following these positive results.